{
    "id": "dbpedia_1175_0",
    "rank": 69,
    "data": {
        "url": "https://vra-pa.com/dr-siva-iyer/",
        "read_more_link": "",
        "language": "en",
        "title": "Dr. Siva Iyer – Vitreo Retinal Associates",
        "top_image": "https://vra-pa.com/wp-content/uploads/2022/10/cropped-Vitreo-Eye-EX-Small-32x32.png",
        "meta_img": "https://vra-pa.com/wp-content/uploads/2022/10/cropped-Vitreo-Eye-EX-Small-32x32.png",
        "images": [
            "https://vra-pa.com/wp-content/uploads/2022/10/VRA-LOGO-with-Text-A-outlines-SM.png",
            "https://vra-pa.com/wp-content/uploads/2022/10/a915e4b708965f88656bdf6d4a3698a6.jpg",
            "https://vra-pa.com/wp-content/uploads/2022/10/VRA-LOGO-with-Text-A-outlines-SM-300x69.png",
            "https://vra-pa.com/wp-content/uploads/elementor/thumbs/Payments-accepted2-q4yzsg1ijlzplnowlvpvtl2i8iabvh62qehuhhfv28.jpg"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": null,
        "summary": "",
        "meta_description": "",
        "meta_lang": "en",
        "meta_favicon": "https://vra-pa.com/wp-content/uploads/2022/10/cropped-Vitreo-Eye-EX-Small-32x32.png",
        "meta_site_name": "",
        "canonical_link": "https://vra-pa.com/dr-siva-iyer/",
        "text": "Education & Board Certification\n\nFellowship – Ophthalmology\n\nLouisiana State University\n\n2013\n\nResidency – Ophthalmology\n\nUniversity of Tennessee\n\n2011\n\nInternship – Surgery\n\nHarvard University\n\n2007\n\nMedical Degree\n\nUniversity of Florida\n\n2006\n\nBoard Certification\n\nOpthalmology – American Board of Ophthalmology\n\nClinical Interests\n\nPublications\n\nIdiopathic Orbital Inflammation in the Postpartum Period Associated With Preeclampsia.\n\nJournal of neuro-ophthalmology: the official journal of the North American Neuro-Ophthalmology Society\n\n2022\n\nThe Vitreous Ecosystem in Diabetic Retinopathy: Insight into the Patho-Mechanisms of Disease.\n\nInternational journal of molecular sciences\n\n2021\n\nPeripheral Retinal Neovascularization in a Patient with Sarcoidosis and Cocaine-Associated Autoimmunity.\n\nCase reports in ophthalmological medicine\n\n2021\n\nExacerbation of pigment epithelial detachment following aflibercept: A case of bevacizumab rescue.\n\nAmerican journal of ophthalmology case reports\n\n2021\n\nEffect of pattern scanning laser on macular thickness in diabetic retinopathy.\n\nTherapeutic advances in ophthalmology\n\n2021\n\nBilateral anterior segment dysgenesis and persistent fetal vasculature associated with terminal 10q26 deletion.\n\nJournal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus\n\n2021\n\nUtility of wound cultures in the management of open globe injuries: a 5-year retrospective review.\n\nJournal of ophthalmic inflammation and infection\n\n2020\n\nTreatment of Recurrent Primary Cutaneous Mucinous Carcinoma of the Eyelid with Modified Wide Local Excision.\n\nCase reports in ophthalmological medicine\n\n2020\n\nEndogenous Endophthalmitis: yield of the diagnostic evaluation.\n\nBMC ophthalmology\n\n2020\n\nEicosanoid Profiles in the Vitreous Humor of Patients with Proliferative Diabetic Retinopathy.\n\nInternational journal of molecular sciences\n\n2020\n\nBilateral pseudohypopyon causing white eyes in a patient with lymphoma.\n\nLancet (London, England)\n\n2020\n\nSurgical management of diabetic tractional retinal detachments.\n\nSurvey of ophthalmology\n\n2019\n\nExercise band-induced lens dislocations: A case series.\n\nAmerican journal of ophthalmology case reports\n\n2019\n\nDosimetric dependence of ocular structures on eye size and shape for external radiation fields of electrons, photons, and neutrons.\n\nJournal of radiological protection : official journal of the Society for Radiological Protection\n\n2019\n\nVision loss secondary to orbital extension of rhabdomyosarcoma in an adult.\n\nClinical & experimental ophthalmology\n\n2018\n\nOphthalmic artery occlusion after chiropractic neck manipulation.\n\nActa ophthalmologica\n\n2018\n\nMultiloculated Ciliary Body Cysts and Lenticular Coloboma: A Rare Phenotypic Variation Associated With Persistent Fetal Vasculature.\n\nJournal of pediatric ophthalmology and strabismus\n\n2018\n\nA scalable and deformable stylized model of the adult human eye for radiation dose assessment.\n\nPhysics in medicine and biology\n\n2018\n\nA Young Patient With Floaters.\n\nJAMA ophthalmology\n\n2018\n\nIntralenticular Ozurdex® – One Year Later.\n\nCase reports in ophthalmology\n\n2017\n\nClinical Research Protocols\n\nHAWK – NCT02307682 – Efficacy and Safety of RTH258 Versus Aflibercept – The purpose of this study is to compare RTH258 ophthalmic solution for intravitreal (IVT) injection at two dosage levels to aflibercept solution for IVT injection (2 mg) in subjects with untreated active choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) in the study eye. – Alcon.\n\nPROXIMA A – NCT02479386 – Epidemiologic Study of Disease Progression in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration – This study seeks to better characterize relationships between visual function and the progression (worsening) of geographic atrophy (GA) due to age-related macular degeneration (AMD). The study is also intended to generate new information on the relationship between genetics and GA progression. – Hoffmann-La Roche.\n\nCEDAR – NCT02462928 – Safety and Efficacy Study of Abicipar Pegol in Patients With\n\nNeovascular Age-related Macular Degeneration – This is a safety and efficacy study of abicipar pegol in patients with neovascular age-related macular degeneration. – Allergan.\n\nORBIT – NCT02079883 – Ocriplasmin Research to Better Inform Treatment – Multicenter, prospective, observational, Phase 4 study assessing clinical outcomes and safety of JETREA® administered in a real-world setting for the treatment of symptomatic vitreomacular adhesion (VMA) by assessing anatomical and functional outcomes. – Thrombogenics.\n\nSHORE – NCT01277302 – A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion – This was a Phase IV multicenter, randomized, open-label study, of the efficacy and safety of intravitreal ranibizumab 0.5 mg in subjects with macular edema following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO). – Genentech.\n\nFOVEA (FOV2304) – NCT01319487 – Safety and Efficacy Study of Topical Administration\n\nof FOV2304 (High Dose or Low Dose) for the Treatment of Center-involving Clinically Significant Macular Edema Associated With Diabetic Retinopathy – The purpose of the study is to determine whether concentrations of FOV2304 (high dose or low dose) administered in the eye are more effective than placebo in treating patients with diabetic macular edema, following 12 weeks of treatment. – Fovea Pharmaceuticals SA.\n\nNovartis HMT – NCT01542866 – A 16-Week Evaluation of the Novartis Health Management Tool (HMT) in Age-Related Macular Degeneration – This is a prospective pilot study to evaluate the usability and applicability of a self-monitoring test of visual function with the handheld Health Management Tool (HMT) to remotely monitor neovascular Age-Related Macular Degeneration (AMD) to detect a potential change in disease status. – Novartis Pharmaceuticals.\n\nDODO (FVF4155s) – NCT00533520 – Evaluation of Dosing Interval of Higher Doses of\n\nRanibizumab – Phase 4 study to test the safety, tolerability and effectiveness of a higher doses (1.0 mg and 2.0 mg) of ranibizumab versus the standard dose (0.5 mg), in adults with age-related macular degeneration who have never been treated with ranibizumab. – Genentech.\n\nVISTA – NCT01363440 – Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema – The purpose of this study is to determine the efficacy of Intravitreal Aflibercept Injection on the best corrected visual acuity (BCVA) in patients with diabetic macular edema (DME) with central involvement.- Regeneron Pharmaceuticals.\n\nForesee Home Device Study (PT US 001) – NCT01334294 – Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular Age-Related Macular Degeneration. – The purpose of the current study is to evaluate if, in post-treatment patients, PHP parameters as measured with the ForeseeHome are in agreement with clinical decisions and retinal characteristics as measured with optical coherence tomography (OCT). – Notal Vision Ltd.\n\nMAHALO – NCT01229215 – A Study of Safety, Tolerability, and Evidence of Activity of\n\nFCFD4514S Administered Monthly or Every Other Month to Patients With Geographic Atrophy – Phase Ib/II, multicenter, randomized, single-masked, sham-injection-controlled study of safety, tolerability, and evidence of activity of FCFD4514S intravitreal injections administered monthly or every other month in patients with geographic atrophy. – Genentech.\n\nResearch Experience\n\n1998-2002 Baylor College of Medicine – Houston, TX\n\nDepartment of Immunology and the Center for Cell and Gene Therapy\n\nAdvisor: Michael A. Barry, Ph.D.\n\nM.D./Ph.D. Candidate – investigated the targeting of retroviral and adenoviral vectors to selected cell types by modifying the viral envelopes and capsid proteins of gene therapy viral vectors\n\n1994-1995 University of Tennessee School of Veterinary Medicine – Knoxville, TN\n\nDepartment of Orthopedic Surgery\n\nAdvisor: Jack Wasserman, Ph.D.\n\nBiomedical Engineering Honors Thesis – tested structural integrity and compared biomechanical properties of a novel PMMA trans-hock external fixation device versus a traditional KE stainless-steel fixation device\n\n1992-93 Oak Ridge National Laboratory – Oak Ridge, TN\n\nChemical Engineering Division Consultant – completed uranium contamination resorption project and trained post-doctoral engineer in newly established protocols\n\n1992 Oak Ridge National Laboratory – Oak Ridge, TN\n\nChemical Engineering Division Research Intern – assisted in the design and testing of a biologically based uranium absorption system for the purification of uranium-contaminated water\n\n1991 Oak Ridge National Laboratory – Oak Ridge, TN\n\nEnergy Sciences Division Research Intern – investigated enhancing the efficiency of heat pump technology through innovative design and use of computer models to test the efficiency of prototype heat pumps\n\nOral Presentations\n\nNov 2015 Oral Platform Presentation – Vision Loss Consequent to Intravitreal Stem Cell Injection\n\nAlbini TA, Kuriyan AE, Townsend JH, Rodriguez M, Pandya HK, Leonard RE, Parrott MB, Rosenfeld PJ, Flynn HW\n\n2015 Annual Meeting – American Academy of Ophthalmology – Las Vegas, NV\n\nNov 2008 Poster – Nosocomial Acute-onset postoperative endophthalmitis at a university teaching hospital Wykoff CC, Flynn HW, Miller D, Parrott MB, Murray TG, Smiddy WE, Davis JL\n\n2008 Annual Meeting – American Academy of Ophthalmology\n\nNov 2007 Poster – Intravitreal bevacizumab use for progressive ROP and Best disease related choroidal neovascular membranes\n\nParrott MB, Murray, TG, and Berrocal AM\n\n2007 Annual Meeting – American Academy of Ophthalmology\n\nJune 2007 Oral Platform Presentation – Nosocomial acute-onset postoperative endophthalmitis survey: An 11-year review of incidence, causative organisms, and outcomes\n\nParrott MB, Wykoff CC, and Flynn HW\n\n43rd Annual Bascom Palmer Eye Institute Resident’s Day – Miami, FL\n\nMay 2007 Poster – Nosocomial acute-onset postoperative endophthalmitis survey: An 11-year review of incidence, causative organisms, and outcomes\n\nParrott MB, Wykoff CC, Miller D, Newton J, and Flynn HW\n\nARVO 2007 Annual Meeting – Fort Lauderdale, FL\n\nJune 2003 Oral Platform Presentation – Metabolically Biotinylated Viruses for Vector Targeting and Purification Campos SK, Parrott MB, Adams KE, and Barry MA\n\nSixth Annual Meeting of the American Society of Gene Therapy – Washington, DC\n\nMarch 2003 Poster – Metabolically biotinylated gene therapy vectors for vector targeting and purification\n\nCampos SK, Parrott MB, Adams KE, Blum JS, Mok H, Muzykantov V, and Barry MA\n\nCold Spring Harbor Symposium on Vector Targeting Strategies for Gene Therapy – Cold Spring Harbor, NY\n\nMarch 2003 Poster – Selection and application of CLL-targeting peptides using peptide-presenting phage libraries\n\nTakahashi S, Mok H, Parrott MB, Marini FC, Andreeff M, Brenner MK, and Barry MA\n\nCold Spring Harbor Symposium on Vector Targeting Strategies for Gene Therapy – Cold Spring Harbor, NY\n\nJan. 2003 Poster – Apoptosis, mitotic rate, and age correlations in the regression of periorbital hemangiomas\n\nParrott MB, Font RL, and Chevez-Barrios P\n\nEighty-Second Annual Texas Society of Pathologists Meeting – Houston, TX\n\nJune 2002 Oral Platform Presentation – Metabolically biotinylated adenoviral vectors for targeted gene therapy\n\nParrott MB and Barry MA\n\nFifth Annual Meeting of the American Society of Gene Therapy – Boston, MA\n\nMay 2002 Oral Platform Presentation – Use of in vivo biotinylated adenoviral vectors for targeted gene therapy\n\nParrott MB and Barry MA\n\nForty-Third Annual National Student Research Forum – Galveston, TX\n\nDec. 2001 Poster – Selection of leukemia-targeting peptides using peptide presenting phage libraries\n\nTakahashi S, Barry ME, Parrott MB, Brenner MK, and Barry MA\n\nForty-Third American Society of Hematology Annual Meeting – Orlando, FL\n\nJune 2001 Poster – Metabolically biotinylated gene therapy vectors\n\nParrott MB and Barry MA\n\nFourth Annual Meeting of the American Society of Gene Therapy – Seattle, WA\n\nMarch 2001 Oral Platform Presentation – Metabolically biotinylated adenoviral and retroviral vectors\n\nParrott MB and Barry MA\n\nCold Spring Harbor Symposium on Vector Targeting Strategies for Gene Therapy – Cold Spring Harbor, NY\n\nJune 2000 Poster – Metabolic biotinylation of recombinant proteins for viral gene therapy vector targeting\n\nParrott MB and Barry MA\n\nThird Annual Meeting of the American Society of Gene Therapy – Denver, CO\n\nMarch 1999 Poster – Selecting lung targeting peptides in vivo\n\nParrott MB and Barry MA\n\nCold Spring Harbor Symposium on Vector Targeting Strategies for Gene Therapy – Cold Spring Harbor, NY\n\nTeaching Experience\n\n2009-2010 – Chief Resident, BPEI\n\n2006-2009 – Teaching Assistant for Neuro-Ophthalmology Course, BPEI\n\n1997-2004 – Teaching Assistant and Graduate Lecturer, Department of Immunology, BCM\n\n2003 – Conference Leader, Department of Pathology, BCM\n\n1996-1999 – Conference Leader and Graduate Lecturer, Physiology, BCM\n\n1996-2000- Student Affairs Tutor, Biochemistry and Physiology, BCM\n\n1995 – Engineering Specialty Course – Tennessee Governor’s School for the Sciences, UTK\n\nGrants and Fellowships\n\n2003-2004 – American Medical Association Foundation Research Seed Grant\n\n1999-2002 – National Research Service Award from National Institutes of Health\n\n1995-2004 – National Institutes of Health – Medical Scientist Training Program Grant\n\nProfessional Organizations"
    }
}